Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-28
2007-08-28
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S324000
Reexamination Certificate
active
11383229
ABSTRACT:
Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
REFERENCES:
patent: 6022307 (2000-02-01), Salvati et al.
patent: 6265411 (2001-07-01), Thomas et al.
patent: 6294532 (2001-09-01), Thomas et al.
patent: 6316603 (2001-11-01), McTigue et al.
patent: 2003/0004174 (2003-01-01), Armistead et al.
patent: 0 002 341 (1978-11-01), None
patent: 0 945 443 (1999-09-01), None
patent: 0 787 742 (2001-12-01), None
patent: 96/05177 (1996-02-01), None
patent: 97/19065 (1997-05-01), None
patent: 97/22596 (1997-06-01), None
patent: 97/30035 (1997-08-01), None
patent: 97/32856 (1997-09-01), None
patent: 97/34786 (1997-09-01), None
patent: 98/18782 (1998-05-01), None
patent: 98/54093 (1998-12-01), None
patent: 99/16755 (1999-04-01), None
patent: 99/60630 (1999-11-01), None
patent: 99/62890 (1999-12-01), None
patent: 00/02871 (2000-01-01), None
patent: 00/12089 (2000-03-01), None
patent: 00/12485 (2000-03-01), None
patent: 00/14105 (2000-03-01), None
patent: 00/21955 (2000-04-01), None
patent: 00/39101 (2000-07-01), None
patent: 00/43373 (2000-07-01), None
patent: 00/47212 (2000-08-01), None
patent: 00/52470 (2000-09-01), None
patent: 00/53595 (2000-09-01), None
patent: 00/53605 (2000-09-01), None
patent: 00/59892 (2000-10-01), None
patent: 00/63204 (2000-10-01), None
patent: 00/73264 (2000-12-01), None
patent: 01/00213 (2001-01-01), None
patent: 01/09134 (2001-02-01), None
patent: 01/14375 (2001-03-01), None
patent: 01/17995 (2001-03-01), None
patent: 01/25220 (2001-04-01), None
patent: 01/40218 (2001-06-01), None
patent: WO-01/47921 (2001-07-01), None
patent: 01/60816 (2001-08-01), None
patent: 01/64654 (2001-09-01), None
patent: 01/64656 (2001-09-01), None
patent: WO-01/64655 (2001-09-01), None
patent: 01/74296 (2001-10-01), None
patent: 02/22601 (2002-03-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Sennlaub et al., The Journal of Clinical Investigation 107(6): 717-725, 2001.
Connell, et al., “Patent Focus on Cancer Chemotherapies. II Angiogenesis Agents: Apr. 2000-Sep. 2000,”Exp. Opinion Ther. Patients(2001), 11(1), pp. 77-114.
Ghosh, Dolly, “2,4-Bis(Arylamino)-6-Methyl Pyrimidines as Antimicrobial Agents,”J. Indian Chem. Soc., vol. LVIII, May 1981, pp. 512-513.
Shawyer et al., “Receptor Tyrosine Kinases as Targets for Inhibition of Angiogenesis,”DDT, vol. 2, No. 2, Feb. 1997, pp. 50-63.
Klement, et al., “Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without over toxicity,”Journal of Clinical Investigation, Apr. 2000, vol. 105, No. 8, pp. 15-24.
Kerbel, Robert S., “A cancer therapy resistant to resistance,” Nature, vol. 390, Nov. 1997, pp. 335-336.
Kerdawy, et al., “Synthesis of Certain Esters of Pteroyl Glutamic Acid Analogues Structurally Related To Antimetabolite Anticancer Compounds,” J. Pharm. Sci. U.A.R., vol. 9, pp. 1-6 (1968).
Ghosh, et al., “2,4 BIS(p-Chloroanilino)-Pyrimidine, An Uncoupler of Oxidative Phosphorylation,” FEBS Letters, vol. 4, No. 3, Aug. 1969, pp. 157-159.
Arutyunyan, et al., “Certain Peculiarities in the Reaction of Uracils with Phosphoric Acid Amides,”N.D. Zelinski Institute of Organic Chemistry, Academy of Sciences of the USSR, pp. 848-853.
Pinedo et al., “Translation Research: The Role of VEGF in Tumor Angiogenesis,”The Oncologist, vol. 5 (supp. 1), 2000, pp. 1-2.
Carter, “Clinical Strategy for the Development of Angiogenesis Inhibitors,”The Oncologist, vol. 5 (supp. 1), 2000, pp. 51-54.
Verbeul, et al., “Targeting Vascular Endothelial Growth Factor Blockade: Ascites and Pleural Effusion Formation,”The Oncologist, vol. 5 (supp. 1), 2000, pp. 45-50.
Gasparini, “Prognostic Value of Vascular Endothielial Growth Factor in Breast Cancer,”The Oncologist, vol. 5 (supp. 1), 2000, pp. 37-44.
McMahon, “VEGF Receptor Signaling in Tumor Angiogenesis,”The Oncologist, vol. 5 (supp. 1), 2000, pp. 3-10.
Ellis, et al., “Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic Implications,”The Oncologist, vol. 5 (supp. 1), 2000, pp. 11-15.
Vajkoczy, et al., “Measuring VEGF-Flk-1 Activity and Consequences of VEGF-Flk-1 Targeting In Vivo Using Intravital Microscopy: Clinical Applications,”The Oncologist, vol. 5 (supp. 1), 2000, pp. 16-19.
Rose, “Antiangiogenic Strategies and Agents in Clinical Trials,”The Oncologist, vol. 5 (supp. 1), 2000, pp. 20-27.
Arasteh, et al., “The Role of Vascular Endothelial Growth Factor (VEGF) in AIDS-Related Kaposi's Sarcoma,”The Oncologist, vol. 5 (supp. 1), 2000, pp. 28-31.
Harris, “von Hippel-Lindau Syndrome: Target for Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Therapy,”The Oncologist, vol. 5 (supp. 1), 2000, pp. 32-36.
Russian Article #1, pp. 7-18.
Russian Article #2, pp. 1304-1307.
Boloor Amogh
Cheung Mui
Davis Ronda
Harris Philip Anthony
Hinkle Kevin
Balasubramanian Venkataraman
Fox Jennifer L.
SmithKline Beecham Corporation
LandOfFree
Pyrimidineamines as angiogenesis modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidineamines as angiogenesis modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidineamines as angiogenesis modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3883984